Home Cart Sign in  
Chemical Structure| 38101-59-6 Chemical Structure| 38101-59-6

Structure of Oglufanide
CAS No.: 38101-59-6

Chemical Structure| 38101-59-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Oglufanide is inhibitor of vascular endothelial growth factor (VEGF) that suppresses angiogenesis.

Synonyms: L-Glutamyl-L-tryptophan; H-Glu-Trp-OH; NSC-334073

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Oglufanide

CAS No. :38101-59-6
Formula : C16H19N3O5
M.W : 333.34
SMILES Code : OC([C@H](CC1=CNC2=C1C=CC=C2)NC([C@H](CCC(O)=O)N)=O)=O
Synonyms :
L-Glutamyl-L-tryptophan; H-Glu-Trp-OH; NSC-334073
MDL No. :MFCD00037953
InChI Key :LLEUXCDZPQOJMY-AAEUAGOBSA-N
Pubchem ID :100094

Safety of Oglufanide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Oglufanide

RTK

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00017303 Ovarian Cancer ... More >> Primary Peritoneal Cavity Cancer Less << Phase 2 Unknown - United States, California ... More >> Comprehensive Cancer Center Glendale, California, United States, 91204 Community Hospital of Los Gatos Los Gatos, California, United States, 95032 Stanford University Medical Center Stanford, California, United States, 94305-5408 United States, District of Columbia Lombardi Cancer Center Washington, District of Columbia, United States, 20007 United States, Georgia Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Kansas University of Kansas School of Medicine-Wichita Wichita, Kansas, United States, 67214 United States, Minnesota University of Minnesota Cancer Center Minneapolis, Minnesota, United States, 55455 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Nebraska University of Nebraska Medical Center Omaha, Nebraska, United States, 68198-3330 United States, Nevada Women's Cancer Center - Las Vegas Las Vegas, Nevada, United States, 89030 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263-0001 United States, North Carolina Lineberger Comprehensive Cancer Center, UNC Chapel Hill, North Carolina, United States, 27599-7295 United States, Ohio Cleveland Clinic Taussig Cancer Center Cleveland, Ohio, United States, 44195 Arthur G. James Cancer Hospital - Ohio State University Columbus, Ohio, United States, 43210-1240 United States, Pennsylvania Magee-Womens Hospital Pittsburgh, Pennsylvania, United States, 15213-3180 United States, Vermont Fletcher Allen Health Care - Medical Center Campus Burlington, Vermont, United States, 05401 United States, Washington Fred Hutchinson Cancer Research Center Seattle, Washington, United States, 98109-1024 University of Washington School of Medicine Seattle, Washington, United States, 98195 United States, Wisconsin University of Wisconsin Comprehensive Cancer Center Madison, Wisconsin, United States, 53792-6164 Less <<
NCT00006037 Colorectal Cancer Phase 2 Terminated(Drug not available) - United States, California ... More >> USC/Norris Comprehensive Cancer Center and Hospital Los Angeles, California, United States, 90033-0804 Less <<
NCT00003773 Ovarian Cancer Phase 1 Completed - United States, California ... More >> USC/Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033-0800 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.00mL

0.60mL

0.30mL

15.00mL

3.00mL

1.50mL

30.00mL

6.00mL

3.00mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories